Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

MAIA

MAIA News

Newswire

04:02

MAIA Biotechnology shares rise 11.87% premarket after CEO and directors buy 182,445 shares, citing confidence in ateganosine’s clinical development.

11:04

MAIA Biotechnology Directors Buy 100,000 Shares at $1.04-$1.14/Share

10:28

MAIA Biotechnology shares surge 20.34% intraday after CEO/board bought 182,445 shares and reported 38% response rate, 17.8-month survival in ateganosine's phase II NSCLC trial.

09:56

MAIA Biotechnology shares surge 11.44% intraday as CEO and board members buy 182,445 shares, and core drug ateganosine shows 38% response rate in NSCLC trial.

09:24

MAIA Biotechnology Executives Buy $194,000 Worth of Company Stock.

View More

About MAIA

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More